A comparision of clinical efficacy in Mixed Protamine Zinc Recombinant Human Insulin Lispro Injection(25R)- and Humalog Mix25-treated patients with type 2 diabetes

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800015829

Enrollment

Unknown

Registered

2018-04-23

Start date

2018-04-17

Completion date

Unknown

Last updated

2018-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes

Interventions

A: Mixed Protamine Zinc Recombinant Human Insulin Lispro Injection(25R)

B:Humalog Mix25

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: newly diagnosed T2D,patients aged between >18 and 9.0% at diagnosis.

Exclusion criteria

Exclusion criteria: serum creatinine levels =1.5 mg/dL (males), =1.4 mg/dL (females) or abnormal creatinine clearance, known hypersensitivity to metformin or insulin, acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma.

Design outcomes

Primary

Measure	Time frame
MBG;	—

Countries

China

Contacts

Public ContactJianhua Ma

Nanjing First Hospital

majianhua196503@126.com+86 18951670116

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 23, 2026